There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The human coagulation factor VIII (FVIII) and von Willebrand factor (VWF) are two
distinct glycoproteins that circulate in the plasma as a non-covalently bound complex
(VWF/FVIII complex). Deficiencies or structural defects in FVIII and VWF are responsible
for the most common inherited plasma bleeding disorders haemophilia A and von Willebrand
disease (VWD), respectively. Current therapies for the treatment of haemophilia have
favourable efficacy, tolerability and safety profiles. However, multiple, frequent
infusions are usually required to manage a bleeding episode, owing to the short half-life
of FVIII. This makes treatment inconvenient and impacts patient quality of life. Several
strategies are currently being pursued in an attempt to reduce the number of infusions
required per bleeding episode. One of the more promising approaches involves prolonging
the half-life of FVIII. This article summarizes the methods that are being used to
extend FVIII half-life.